Name | Value |
---|---|
Revenues | 2,397.7K |
Cost of Revenue | 1,558.8K |
Gross Profit | 838.9K |
Operating Expense | 2,926.7K |
Operating I/L | -2,087.8K |
Other Income/Expense | -17.1K |
Interest Income | 5.2K |
Pretax | -2,104.9K |
Income Tax Expense | 5.4K |
Net Income/Loss | -2,110.3K |
Affinity Technologies, Inc. is a biotechnology company specializing in non-invasive diagnostic tests and targeted cancer therapeutics. Their flagship product, CyPath lung, is a non-invasive diagnostic test designed for early detection of lung cancer. In addition to diagnostic tests, the company is involved in researching targeted therapies to treat cancer at the cellular level, aiming to provide effective treatment solutions. By developing and commercializing non-invasive diagnostic tests and targeted cancer therapeutics, the company generates revenue through product sales and potentially through partnerships and collaborations within the healthcare industry.